However, concerns about cumulative radiation exposure from multiple tests, 3-5 the overall low proportion of obstructive CAD in patients referred for ICA, 6,7 and the implications of the Clinical Trials Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial 8 suggesting a more conservative approach make less invasive and non-radiationbased diagnostic alternatives desirable.
T he evaluation of patients presenting with chest pain or other symptoms suggestive of coronary artery disease (CAD) is a common clinical challenge. A history and physical examination followed by a stress test, without or with myocardial perfusion imaging (MPI), make up most evaluations. In the United States, MPI is most commonly performed; 6.8 million patients underwent such tests in 2009. 1 Direct referral to invasive coronary angiography (ICA) or computed tomographic angiography (CTA) 2 in place of or after positive stress tests is another common pathway.
We previously developed and validated a peripheral blood gene expression score (GES) to assess obstructive CAD likelihood in nondiabetic patients referred for ICA and analyzed by core-laboratory quantitative coronary angiography (QCA) in the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) study (NCT005617). 9, 10 The score algorithm was derived by the use of Ridge regression from 640 patients for whom real-time polymerase chain reaction gene expression data and QCA had been obtained. 9 This algorithm comprises expression values for 23 genes from peripheral blood cells in 6 terms, patient age, and sex as shown in Figure 1 . Each term is composed of ratios of highly correlated genes representing a diverse set of inflammatory cell biology, including neutrophil apoptosis, neutrophil-to-lymphocyte ratio, and natural killer-cell activation. There are both sex-specific and common algorithm terms with sex-specific weights. Subsequently, we showed that patients with low GES (≤15) had very low rates of revascularizations and adverse events over 1 year 11 and that the GES appeared to be especially useful in women. 12 A limitation of the PREDICT study was selection bias inherent in the angiographically referred population, 13 and the accuracy of the GES in a lower-CAD-prevalence population is unknown. Accordingly, we designed the Coronary Obstruction Detection by Molecular Personalized Gene Expression (COMPASS) study to extend this work upstream in the referral path to symptomatic nondiabetic patients referred for MPI using a composite hierarchical anatomic end point of QCA and core-laboratory CTA to define obstructive CAD status in all participants. Thus, COMPASS enables an assessment of GES and MPI performance in a lower-risk population while minimizing selection bias.
Methods

Study Design
The COMPASS study was a multicenter, prospective, double-blind, diagnostic clinical study. We enrolled 537 patients at 19 US sites, both community and academic centers (Appendix II in the online-only Data Supplement); of these, 431 patients were evaluable, having completed the protocol prespecified testing: GES, MPI, and ICA or research CTA.
Patients were enrolled from May 2010 to March 2011. The Institutional Review Board at each center or a central Institutional Review Board approved the study, and all patients provided written informed consent. Patients referred for diagnostic MPI stress testing with angina or anginaequivalent symptoms were eligible. Exclusion criteria included history of myocardial infarction (MI) or CAD, acute MI, diabetes mellitus or hemoglobin A 1c >6.5%, New York Heart Association class III or IV heart failure symptoms, cardiomyopathy with ejection fraction ≤35%, severe cardiac valvular diseases, systemic infectious or inflammatory conditions, or treatment with immunosuppressive or chemotherapeutic agents at study entry. For patients requiring a research CTA, additional exclusion criteria were atrial fibrillation, known renal insufficiency (creatinine ≥2.0 mg/dL), or severe iodinated contrast allergy.
Peripheral blood was collected before MPI for GES measurements. Subjects with positive MPI underwent ICA on the basis of clinical Figure 1 . Schematic of gene expression score algorithm. The algorithm consists of overlapping gene expression functions for men and women with sex-specific coronary artery disease (CAD) age dependencies. The algorithm gene expression terms and their biological or cellular pathways are shown. The genes symbols are as follows: IL18RAP, interleukin-18 receptor-associated protein; TNFAIP6, tumor necrosis factor-α-induced protein 6; CASP5, caspase-5; IL8RB, interleukin-8 receptor β; TNFRSF10C, TRAIL decoy receptor 3; TLR4, Toll-like receptor-4; KCNE3, ISK family potassium voltage-gated channel; S100A8, S100 calcium-binding protein 8; S100A12, S100 calcium-binding protein 12; CLEC4e, C-type lectin domain family 4e; RPL28, ribosomal protein 28 light subunit; AQP9, aquaporin 9; NCF4, neutrophil cytosolic factor 4; SLAMF7, SLAM family member 7; KLRC4, killer cell lectin receptor family C4; TMC8, transmembrane channel-like-8; CD3D, CD3-δ; SPIB, spi-B transcription factor; CD79B, immunoglobulin associated CD79B; AF2, AF289562, unknown protein; TSPAN, AF161365, unknown protein; TFCP2, transcription factor CP2; and HNRPF, heterogeneous nuclear riboprotein F. The gene expression score is calculated from median Cp values as follows: raw score=intercept−0.755×(N up −N down )−0.308×sex×(SCA 1 − Norm 1 )−0.548×(1−sex)×(SCA 1 −Neut)−0.406×(NK up −T cell )−0.137×(B cell −T cell )−0.482×sex×(TSPAN)−0.246 (AF2−Norm 2 ). For men (SEX=1) and women (sex=0), intercept=2.672+0.0449×Age and 1.821+0.123×(Age−60), respectively, with only positive values allowed for women; N up =1/3×(CASP5+IL18RAP+TNFAIP6), N down =0.25×(IL8RB+TNFRSF10C+TLR4+KCNE3); SCA 1 =1/3×(S100A12+S100A8+CLEC4E); Norm 1 =RPL28; Neut=0.5×(AQP9+NCF4); NK up =0.5×(SLAMF7+KLRC4); T cell =0.5×(CD3D+TMC8); B cell =2/3×CD79B+1/3×SPIB; TSPAN=1 if (AF161365−Norm2)>6.27 otherwise 0; and Norm 2 =0.5×(HNRPF+TFCP2). The final score is transformed to the integer 1 to 40 scale for clinical reporting as described in Methods in the online-only Data Supplement. Adapted from Elashoff et al. 9 judgment; all others had research CTA. This established anatomic reference data for all patients and attenuated the impact of referral bias on test performance estimates. Patients were followed up for 6 months after index MPI and GES with clinical end points defined as major adverse cardiac events I (MACEs); nonfatal MI, stroke/transient ischemia attack, and all-cause mortality) and revascularization (Appendix III in the online-only Data Supplement).
Clinical Estimations of CAD Likelihood
The clinical pretest probability of CAD was estimated by 2 methods: the Diamond-Forrester classification 14 and the Morise score. 15, 16 
Stress MPI and Angiography
All subjects underwent single-photon emission computed tomography MPI based on site standard of care with either exercise (78%) or pharmacological (22%) stress, with stress-only imaging in 22% (4% with attenuation correction). Patients were classified as MPI negative (normal or fixed defect interpreted as artifact) or MPI positive (reversible or fixed perfusion defect in any myocardial segment). Site MPI interpretation was used to reflect real-world MPI use and core-laboratory evaluation completed to provide an expert interpretation for secondary analysis (Appendix III in the online-only Data Supplement).
ICA was performed according to institutional protocols, with at least 2 orthogonal views of the major coronary arteries. CTA image acquisition and reconstruction parameters were based on local institutional protocols on ≥64-slice multidetector CT systems. β-Blockade was encouraged to achieve heart rate of ≤65 bpm and sublingual nitroglycerin for vasodilation. For local CTA image analysis, investigators interpreted scans on the basis of a modified 17-segment American Heart Association coronary segmentation model. 17 Core-laboratory evaluations were performed for ICA by QCA and for coronary CTA by 2 independent readers to define obstructive CAD anatomic reference standards (Appendix III in the online-only Data Supplement).
CAD and Clinical Events Definitions
Obstructive CAD was defined prospectively as ≥1 stenosis ≥50% in a major vessel on QCA (≥1.5 mm) or CTA (≥2.0 mm). If QCA results were obtained, they were used; otherwise, core-laboratory CTA defined obstructive CAD. Patients with obstructive CAD were defined as cases and others as controls for dichotomous analyses. A subset of patients (n=28) with both QCA and core-laboratory CTA were used for intermethod comparisons. Mild CAD was defined as ≥25% to 49% stenosis.
Clinical end points were predefined as all revascularizations and MACEs (nonfatal MI, stroke/transient ischemic attacks, or all-cause mortality) both within 30 days of the index MPI and subsequently during follow-up.
GES Determination
Venous blood samples were collected before MPI in PAXgene RNA preservation tubes (PreAnalytiX, Valencia, CA) according to the manufacturer's instructions and stored at −20°C. Automated RNA purification, cDNA synthesis, and real-time polymerase chain reaction were performed as described, 10, 18 according to Corus CAD protocols in a Clinical Laboratory Improvement Amendments-approved reference laboratory (CardioDx, Inc, Palo Alto, CA). Raw GESs were computed from median expression values for the 23 algorithm genes, age, and sex and linearly transformed to a 1 to 40 scale for reporting ( Figure 1 ; Appendix I in the online-only Data Supplement). 10
Statistical Analysis
A prospectively defined analysis plan (Appendix IV in the onlineonly Data Supplement) was communicated to the external statistician (M.E.W.) before study completion, and primary and secondary analyses were performed starting from individual well real-time polymerase chain reaction data. The primary end point of GES area under the curve (AUC) superiority to 0.5 was powered to >90% (2-sided α=0.05) with 376 subjects and 62 cases assuming an AUC of 0.70. Sensitivity, specificity, negative predictive value (NPV), and positive predictive value were calculated at a prespecified GES threshold of ≤15 (>15 is GES positive, ≤15 is GES negative) from our previous validation study. 10 Referral bias correction was performed as described by Diamond. 19 Se q p ASe q p Sp p q ASp p q
Se is true sensitivity; Sp is true specificity; ASe is apparent (biased) sensitivity; ASp is apparent (biased) specificity; p is referral rate for positive tests; q is referral rate for negative tests. All analyses were performed with R, version 2.13 (Hmisc, pROC, ROCR, verification, and SDMTools packages). 20 Unless otherwise specified, univariate comparisons used t tests for continuous variables and χ 2 tests for categorical variables. All reported P values are 2 sided. Standard methods were used to estimate receiver-operating characteristics (ROC) curves and associated AUCs with the Z test to discriminate AUCs from 0.5. For other AUC comparisons, 10 000 bootstrap iterations were performed, and P values were estimated from the empirical distribution of bootstrapped AUC differences. 10 GES correlation with maximum percent stenosis was estimated by linear regression and the Pearson correlation coefficient (r). Influence of demographic and clinical factors was assessed with a linear regression model in which the gene expression portion of the GES was the dependent variable and the independent variables were the factors in Table 1 (apart from age and sex, which are incorporated into the GES algorithm).
Reclassification of disease status using the GES in patients after MPI was assessed by net reclassification improvement (NRI) 21,22 using 3 GES categories (low, ≤15; intermediate, 16-27; and high, ≥28). A successful reclassification was defined as a patient without obstructive CAD with positive MPI and a low GES (≤15) or with obstructive CAD and negative MPI with a high GES (≥28). NRI for the GES represents patients correctly reclassified from an incorrect MPI classification minus those incorrectly reclassified by GES from a correct MPI classification. For comparison with clinical factors, the pretest probability was divided into 3 categories: low (<15%), medium (15%-50%), or high (>50%) likelihood. 10
Results
Patient Flow and CAD Prevalence
This study enrolled 537 patients at 19 sites who were clinically referred for MPI and had a blood sample obtained for GES measurement before stress testing, with coronary anatomy assessed by ICA if clinically indicated and by research CTA otherwise ( Figure 2) . A final cohort of 431 patients was evaluable having completed all prespecified diagnostic tests: MPI, GES, and core-laboratory assessed CTA or ICA. Patient exclusions were attributable primarily to 90 subjects declining a research CTA after a negative MPI.
The clinical and demographic characteristics of this 431-patient cohort are shown in Table 1 . Characteristics associated with obstructive CAD were older age, male sex, higher systolic blood pressure, dyslipidemia, smoking, and prescription of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors, whereas symptoms, ethnicity, and body mass index were not. The proportions of patients with low, intermediate, and high Diamond-Forrester CAD likelihoods were 58%, 17%, and 25%, respectively. Obstructive CAD was present in 63 patients (15%): 17 patients with positive MPIs and 46 with negative MPIs (Figure 2 ). Obstructive disease was identified in 29 patients by QCA and in 34 by core-laboratory CTA. Of these, 35 had 50% to 69% stenosis and 28 had 70% to 100% stenosis. Comparing site with core-laboratory reads for angiography and CTA showed a consistent shift to lower percent stenosis in core-laboratory reads, with median shifts of 15% and 22%, respectively. For the 28 patients with both QCA and CTA core-laboratory data, case:control status agreement was 86% (κ=0.72), with only a 1% median stenosis difference between these results (P=NS). An additional 92 patients (21%) had mild CAD (25%-49% stenosis).
GES Performance
The GES (Figure 1 ) was developed and validated in a series of studies involving >1000 patients. 9, 10 In the present study, the GES was a highly significant predictor of obstructive CAD by ROC analysis (AUC=0.79; 95% confidence interval [CI], 0.73-0.84; P<0.001; Figure 3 and Table 2 ). Sensitivity and specificity of the GES were 89% and 52%, respectively, with NPV and positive predictive value of 96% and 24%, with 199 patients (46%) below the prespecified threshold of ≤15. The GES added to clinical factors by both ROC analysis ( Figure 3 ) and NRI using either Diamond-Forrester or Morise classifications (NRI=28% and 60%, respectively; Table 2 ). The GES was not significantly affected by demographic or clinical covariates, including ethnicity, smoking status, body mass index, dyslipidemia, and systolic blood pressure, or medications (aspirin, statins, β-blockers, and angiotensin-converting enzyme inhibitors; all P>0.1; Table I in the online-only Data Supplement). The GES was significantly correlated with maximum percent stenosis (r=0.46; P<0.001). The continuous relationship between CAD likelihood and GES is shown for ≥25% and ≥50% stenosis ( Figure 4A) ; a categorical representation using the prespecified GES thresholds of 15 and 28 is shown in Figure 4B .
Patients were followed up for 6 months after index MPI and GES, with 97% (420 of 431) completing follow-up. There were 28 adverse clinical events noted, including 25 revascularizations within 30 days, 1 further revascularization, and 2 MACEs over the next 5 months. A total of 25 of 26 patients with revascularizations and both patients with MACEs had GES >15. The GES was associated with MACEs and revascularization likelihood in a logistic regression model (P=0.0015) and showed a sensitivity of 96% and NPV of 99% at a score threshold of ≤15.
MPI Performance
Local-site MPI scans were reported as positive in 48 of 431 patients (11%) and 51 of 371 patients (14%) by core laboratory with 87% concordance. Site-read image quality was rated as excellent in 210, very good in 72, good in 127, and poor in 22 patients. Overall core-laboratory interpreter certainty was high (279), fair (76), and low (16) . MPI was significant in predicting obstructive CAD (≥50% stenosis) by both site and core-laboratory reads (AUC=0.59; 95% CI, 0.54-0.65; and AUC=0.63; 95% CI, 0.57-0.70; P<0.001, respectively; Figure  5 ). For patients with ≥70% stenosis (n=28), these increased to 0.63 and 0.67, respectively, whereas the GES AUC was 0.76. Site-read and core-laboratory MPI had sensitivities of 27% and 36% and specificities of 92% and 90%, respectively; the NPVs and positive predictive values are shown in Table 2 . The GES outperformed site-read MPI as a predictor of obstructive CAD by ROC and NRI (∆AUC=0.19; NRI=26%; both P<0.001) and by ROC for core-laboratory MPI (∆AUC=0.16; P<0.001; NRI=11%; P=0.13; Figure 5 and Table 2 ). To further illustrate the relationships between stenosis category (<25%, 25%-49%, and ≥50%), MPI, and GES results, a dot plot for the 371 patients with core-laboratory MPI and GES results is shown in Figure I in the online-only Data Supplement. In the 6-month follow-up, site and core-laboratory MPI were positive in 11 and 14 early revascularizations and 0 and 1 of 3 events/late revascularizations, yielding sensitivities of 39% and 54%, respectively, and NPVs of 96% for both.
To account for potential verification bias on MPI diagnostic accuracy from the 90 patients not undergoing CTA, we performed a sensitivity analysis assuming that these MPI 
Discussion
This multicenter, prospective study assessed the diagnostic accuracy of a peripheral blood GES to discriminate obstructive CAD in symptomatic nondiabetic patients clinically referred for MPI, extending our previous work in patients clinically referred for ICA. 10 This study has 4 major findings. First, the GES showed strong discrimination for obstructive CAD (AUC=0.79; 95% CI, 0.73-0.84; P<0.001) in this independent, community-based, lower-risk population and was superior to clinical estimates by Diamond-Forrester and Morise scores (∆AUC=0.10; P=0.003; and ∆AUC=0.12; P=0.002), respectively. Second, the GES was proportional to maximum percent stenosis, as seen previously. 10 Third, the GES outperformed site-read and core-laboratory MPI for discrimination of obstructive CAD (∆AUC=0.19 and 0.16; both P<0.001). Finally, we demonstrated good agreement between QCA and core-laboratory CTA in case definitions, validating the composite anatomic end point. The GES is based on peripheral blood cell gene expression levels of 23 genes, age, and sex and reflects changes in peripheral blood gene expression and cell-type distributions in the presence of CAD. 9, 10 Clinical practice guidelines for the management of patients with CAD and for revascularization are largely predicated on obstructive CAD; therefore, the prespecified primary end point of the present study was the identification of anatomically obstructive CAD. All patients with GES and MPI results had QCA or core-laboratory CTA to identify obstructive CAD. GES performance was consistent with the PREDICT study validation (AUC=0.79±0.06 versus 0.70±0.04) 10 and similar to the cross-validated estimate of 0.77 from test development. 9 As expected, obstructive disease prevalence in this patient population (15%) was significantly lower than that in the PREDICT study (37%) and in a large angiography registry. 6 This leads to the higher GES NPV in this MPI-referred population (96%) compared with the angiographic population (83%) and a larger proportion of patients with scores ≤15 (46% versus 33%). The optimal GES threshold, maximizing the sum of Figure 4 . A, Likelihood of coronary artery disease (CAD) and obstructive CAD as a continuous function of gene expression score (GES). The percent likelihoods of ≥25% stenosis (mild and obstructive CAD) and ≥50% stenosis (obstructive CAD) are indicated by the green and red lines, respectively, as a function of GES, with dashed lines representing 95% confidence intervals. For a given score, the likelihood of mild or greater CAD is higher than for obstructive CAD. B, Relationship between stenosis category and GES category. The percentages of patients with 0%, 1% to 24%, 25% to 49%, and ≥50% stenosis are shown in prespecified GES categories of 1 to 15, 16 to 27, and 28 to 40. For these GES categories, the patient numbers are 199 (46%), 165 (38%), and 67 (16%), respectively. sensitivity and specificity, was 19 (sensitivity, 84%; specificity, 67%; NPV, 96%; Table II in the online-only Data Supplement) , with 59% of patients below this threshold.
The most common noninvasive imaging modality used in clinical assessment of CAD in the United States is MPI. 23 Thus, this study was designed to assess the GES in this patient population, and a secondary end point was to compare the general community setting performance of MPI with the GES. The 19 sites involved represent a variety of clinical settings, from academic centers to private practices. The GES outperformed MPI by ROC analysis and NRI ( Table 2 ). We previously observed in the angiographic PREDICT study that the GES outperformed site-read MPI by ROC (∆AUC=0.16; P<0.001), but that result was confounded by referral bias of negative MPIs not being referred to ICA. 10 For the 310 patients in the PREDICT validation cohort who had MPI, 72% were positive compared with 11% in COMPASS, suggesting selective patient referral with positive MPIs. However, in both studies, the majority of positive MPIs with low GES were false positives (51 of 57 and 13 of 14, respectively).
Limitations
First, our study was limited to a relatively small nondiabetic, largely white US population without known CAD, previous revascularization or MI, and known inflammatory or autoimmune disorders but with symptoms suggestive of CAD. Both asymptomatic patients and those with high-risk unstable angina were excluded. Diabetics were excluded on the basis of the observation that peripheral blood gene expression classifiers for CAD in diabetics and nondiabetics are distinct, attributable to either medication effects or differences in underlying pathophysiology. 9 These factors together suggest that the subjects enrolled may have lower disease prevalence and severity than typical outpatient populations without known CAD.
Second, 106 patients from the original population of 537 were excluded from analysis, with the large majority (n=90) of patients with negative MPIs who refused research CTA. As noted above, we required an anatomic gold standard for all patients, not just those with positive MPI. Assuming that all these negative MPIs were correct, site-read MPI AUC increased to only 0.60. In addition, 11 patients were lost to follow-up from the 431 in the evaluable set, which could have influenced MACE and revascularization rates. This is unlikely to be significant because 7 of 11 of these had GES ≤15 at baseline and only 1 of 199 with low scores had a revascularization on follow-up.
Third, the GES has high sensitivity and NPV and hence is most suitable as a rule-out test, but 54% of patients had scores >15. These most likely represent patients with nonobstructive CAD but with significant plaque burden and stenosis because the GES was proportional to maximum percent stenosis. As shown in Figure 4B , more than half of the patients with GES >15 had measurable CAD (≥25% stenosis), and this proportion increased with increasing GES. The clinical importance of nonobstructive lesions for disease progression and events was highlighted in the An Imaging Study in Patients with Unstable Atherosclerotic Lesions (PROSPECT) study. 24 Other possible explanations for these higher GES scores without obstructive CAD could be diffuse CAD, atherosclerosis in other vascular beds, or unidentified inflammatory disorders.
Finally, MPI performance in this study was less than expected. Several factors likely contributed to this. First, this study used an anatomic obstructive CAD end point; however, systematic differences would be expected because MPI assesses ischemia. The rationale for an anatomic gold standard was to provide quantitative information across the range of stenosis and because of the prognostic importance of obstructive CAD. [25] [26] [27] However, recent studies comparing MPI and CTAdefined anatomy consistently demonstrate that only 30% to 50% of ≥50% stenoses result in abnormal MPI, [28] [29] [30] lower than cited in the American College of Cardiology 2003 guidelines. 31 Second, this study population was relatively low risk (15% obstructive CAD) and excluded diabetics, inpatients, and those with high-risk symptoms. The mean age of the patient population (56±10 years) was lower and the frequency of exercise versus pharmacological testing (78%) was greater than those observed in another outpatient-only trial (65 ±12 years and 63% exercise versus 37% pharmacological stress). 32 Whereas ischemia is particularly important in assessing the potential benefit of lesion revascularization and intermediate and longterm prognosis, 31 recent outcome studies of patients undergoing CTA demonstrated a stepwise worsening of prognosis from nonobstructive to obstructive CAD. 26, 27 Third, we did not control for inter-reader variability or prespecify a standard image acquisition protocol. Training on specific MPI protocols has been shown to improve inter-reader agreement. 33 A comparison of the GES with other noninvasive imaging modalities such as stress echocardiography or MRI might yield different results.
Finally, studies of cardiovascular imaging modalities, including echocardiography 34, 35 and exercise treadmill, 36 correcting for referral bias have reported diagnostic test performance characteristics that vary significantly from those typically reported. Because patients with positive stress-test results are more likely to undergo follow-up ICA, sensitivity and specificity derived from an angiographic population are overestimated and underestimated, respectively. A recent meta-analysis of MPI studies with angiographic end points found a median sensitivity of 81% and specificity of 65%. 37 When we applied a referral bias correction to these data (see Methods), 19 using recent estimates of angiography referral rates for positive (48.2%) and negative (6.2%) MPI results, 38 the unbiased estimates of MPI performance were 35% sensitivity and 94% specificity. These estimates are very similar to the core-laboratory results obtained in this study, which had minimal referral bias by design, and suggest that our results are consistent with the literature after verification bias removal.
Implications: Atherosclerosis Testing as a Precursor to Ischemia Testing
The correlation of the GES with maximum percent stenosis, the high sensitivity (89%), and the NPV (96%) for obstructive CAD at the prespecified GES threshold of 15 in this symptomatic population with relatively low (15%) CAD prevalence suggest that this test is a highly sensitive measure of coronary atherosclerosis. This is further supported by the GES sensitivity to nonobstructive CAD ( Figure 4B ). Conversely, MPI had high specificity (92%) for obstructive CAD in this population and measures functional ischemia. Together, these results suggest that MPI could be used to risk stratify the enriched population of those with GES above a certain threshold (eg, >15) into those with positive MPI with an ischemic burden or symptom status such that ICA and potential revascularization were warranted and those with negative MPI who would be aggressive medical therapy candidates. Because nonischemic atherosclerotic CAD burden assessed by CTA was shown in the CONFIRM Registry to predict increasing risk of hard cardiac events with increasing nonobstructive CAD, 27 identification and treatment of this group with elevated GES and normal MPI would likely be beneficial. Such a clinical algorithm, illustrated in Figure 6 , would result in 46% fewer MPIs and 29% fewer ICA with a higher yield of obstructive disease (47%) based on site-read MPIs ( Table III in the onlineonly Data Supplement.); similar results (45%, 33%, and 49%, respectively) are obtained with core-laboratory MPI ( Table IV in the online-only Data Supplement) with a few false-negative GESs with positive MPIs. Given the 6-month follow-up data, in which only 1 patient of the 199 with GES ≤15 had a revascularization, this strategy may have significant clinical utility and safety, yielding more appropriate and targeted cardiac imaging and ICA.
In summary, in this second prospective multicenter validation study of a peripheral blood GES for obstructive CAD in nondiabetic patients, the GES showed significant improvement over clinical estimation of CAD and outperformed MPI in identifying anatomically defined obstructive CAD in symptomatic patients. Figure 6 . Clinical algorithm with sequential use of gene expression score (GES) and myocardial perfusion imaging (MPI). Based on the data in this study, the model shown is suggested. For patients with GES ≤15, no further follow-up is proposed given the high sensitivity and negative predictive value at this threshold. The remaining patients (54%) would undergo MPI, and only those with positive MPIs would be referred for invasive coronary angiography (ICA). Such a clinical algorithm results in a 46% reduction in MPI, a 29% reduction in ICA, and an improvement in ICA yield from 35% to 47%.
